Philippine Journal of Otolaryngology Head and Neck Surgery, 2012 Eight cases of primary thyroid lymphoma were reported in a tertiary government hospital from January 2005 to August 2011. All patients presented with a diffuse enlargement of both thyroid lobes with associated obstructive symptoms.
Claudine Ann Musngi-Paras +2 more
doaj +1 more source
Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]
, 2016 B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke +2 more
core +1 more source
BCL-W has a fundamental role in B cell survival and lymphomagenesis. [PDF]
, 2017 Compromised apoptotic signaling is a prerequisite for tumorigenesis. The design of effective therapies for cancer treatment depends on a comprehensive understanding of the mechanisms that govern cell survival.
Annette S. Kim +14 more
core +2 more sources
Spinal cord compression by B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a patient seropositive for human immunodeficiency virus: a case report [PDF]
, 2014 INTRODUCTION: Although non-Hodgkin’s lymphoma is one of the most common and frequently fatal of the acquired immune deficiency syndrome-defining illnesses, survival has improved significantly since the introduction of antiretroviral therapy.
Jun-Yeong Seo +4 more
core +1 more source
Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation [PDF]
, 2019 B cell lymphoma-6 (BCL6) is highly expressed in germinal center B cells, but how its expression is maintained is still not completely clear. Aryl hydrocarbon receptor interacting protein (AIP) is a cochaperone of heat shock protein 90. Deletion of Aip in
Allen +56 more
core +4 more sources
Haematologica, 2014 The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial.
Wyndham H. Wilson +19 more
doaj +1 more source
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience [PDF]
, 2017 Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established efficacy, and a favorable and well-defined safety profile in patients with various CD20-expressing lymphoid malignancies, including indolent and aggressive forms of B ...
A Abulayha +161 more
core +2 more sources
Two Cases of Pelvic Diffuse Large B-Cell Lymphoma
Journal of Investigative Medicine High Impact Case Reports, 2022 Primary diffuse large B-cell lymphoma presenting as an extranodal site in the pelvis is rare and can mimic a gynecological malignancy. Although management for diffuse large B-cell lymphoma is standardized and curative, prognosis depends on timely ...
Rupam Sharma MD +5 more
doaj +1 more source
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy [PDF]
, 2016 Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases.
BETTELLI, Stefania Raffaella +4 more
core +2 more sources
Dramatic radiotherapy response in a necrotic lymphoma mass: a case report
Journal of Medical Case Reports, 2020 Background Diffuse large B-cell lymphoma (DLBCL) represents the most common form of non-Hodgkin lymphoma and is characterized by an aggressive natural history. It often presents with rapid symptom development and disease progression.
Nicholas McNeil +3 more
doaj +1 more source